TriSalus Life Sciences, Inc. (TLSI)
| Market Cap | 275.75M |
| Revenue (ttm) | 45.15M |
| Net Income (ttm) | -69.69M |
| Shares Out | 61.41M |
| EPS (ttm) | -1.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 116,493 |
| Open | 4.490 |
| Previous Close | 4.500 |
| Day's Range | 4.370 - 4.610 |
| 52-Week Range | 3.420 - 7.950 |
| Beta | 0.54 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+55.9%) |
| Earnings Date | May 12, 2026 |
About TLSI
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device... [Read more]
Financial Performance
In 2025, TriSalus Life Sciences's revenue was $45.15 million, an increase of 53.41% compared to the previous year's $29.43 million. Losses were -$69.69 million, 109.7% more than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for TLSI stock is "Strong Buy" and the 12-month stock price target is $7.0.
News
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its inv...
TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its inv...
TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor Models
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational...
TriSalus Life Sciences Earnings Call Transcript: Q4 2025
Revenue grew 60% in Q4 and 53% for the year, driven by commercial execution and product expansion. A $46M public offering strengthened the balance sheet, enabling investments in sales force and clinical studies. 2026 revenue guidance is $60–$62M, with growth weighted to H2.
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational...
TriSalus Life Sciences to Host Fourth Quarter 2025 Financial Results Conference Call
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology-focused medical technology company advancing novel drug delivery technologie...
TriSalus Life Sciences Announces Pricing of $40.0 Million Public Offering
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologie...
TriSalus Life Sciences Proposes Public Offering
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologie...
TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology-focused medical technology company advancing novel drug delivery technologie...
TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologie...
TriSalus Life Sciences Transcript: KOL Event
Pressure-enabled thyroid artery embolization offers a minimally invasive, effective alternative to surgery for large goiters and hyperthyroidism, with high efficacy, low complication rates, and preservation of thyroid function. Early US data and ongoing registry efforts support broader adoption.
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapie...
TriSalus Life Sciences Transcript: Piper Sandler 37th Annual Healthcare Conference
A high-growth oncology company showcased its pressure-enabled drug delivery technology, expanding its device portfolio and applications across multiple indications. Favorable reimbursement, strong clinical outcomes, and a robust IP position support 50% annual growth and near-term profitability.
TriSalus Life Sciences Transcript: CG MedTech, Diagnostics and Digital Health & Services Forum
Pressure-enabled drug delivery technology is driving rapid growth and clinical adoption, with strong reimbursement support and expansion into multiple new indications. Financial performance remains robust, with high margins and a focus on operating leverage as new products and applications accelerate top-line growth.
TriSalus Life Sciences Launches TriNav® XP Infusion System to Expand Options for Pressure-Enabled Drug Delivery™
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tu...
TriSalus Life Sciences Earnings Call Transcript: Q3 2025
Q3 2025 revenue grew 57% year-over-year to $11.6M, driven by strong TriNav adoption and new product launches. Gross margin was 84%, with improved adjusted EBITDA loss and cash burn. Guidance for 50% revenue growth is reaffirmed, with expanding indications and robust commercial momentum.
TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational...
TriSalus Life Sciences Transcript: KOL Event
Key opinion leaders highlighted the clinical and economic advantages of pressure-enabled drug delivery in uterine artery embolization, demonstrating superior fibroid reduction, procedural efficiency, and safety. Education and data-driven outreach are essential to increase adoption and patient access.
TriSalus Life Sciences to Participate in Upcoming Investor Conferences
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapie...
TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapie...
TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapie...
TriSalus Life Sciences Transcript: Cantor Global Healthcare Conference 2025
Management highlighted strong sequential growth, new product launches, and a unique reimbursement code driving adoption. Expansion into new indications and registry studies aim to support guideline inclusion, while operational efficiency and clinical milestones are set for 2026.
TriSalus Life Sciences to Participate in Upcoming September Investor Conferences
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapie...
TriSalus Life Sciences Earnings Call Transcript: Q2 2025
Q2 2025 saw 52% revenue growth year-over-year, driven by strong TriNav adoption, new product launches, and expanded reimbursement. Gross margin dipped to 84% due to new product ramp, but operating losses improved. Guidance for 50% revenue growth and cash flow positivity in early 2026 was reiterated.
TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational...